Dr. Jeppe Skov
“Understanding what a medication does to the body — and what the body does to the medication — is the foundation of any honest treatment discussion.”
Endocrinologist With Doctoral Research in GLP-1 Treatment and Renal Physiology
Dr. Jeppe Skov is a Danish physician specializing in endocrinology and metabolic medicine. His clinical and academic work focuses on GLP-1-based therapy, obesity medicine, type 2 diabetes, hormonal regulation of metabolism, and the effects of incretin-based treatment on kidney function.
Dr. Skov completed his medical training at Aarhus University and undertook doctoral research on the effect of GLP-1 treatment on renal physiology — a narrow but clinically significant area given the increasing use of GLP-1 receptor agonists in patients with concurrent metabolic and kidney conditions. His academic background spans the pharmacology, metabolic outcomes, and patient-level considerations relevant to modern weight-management and diabetes pharmacotherapy.
As Medical Reviewer for weight-management and GLP-1-related content, Dr. Skov evaluates patient-facing articles against current prescribing information, peer-reviewed endocrinology literature, and established treatment guidelines. His role is independent clinical review — he does not write the articles he assesses.
Education and Specialist Training
-
Medicine — Aarhus UniversityMedical Education
-
PhD — Effect of GLP-1 Treatment on Kidney FunctionDoctoral Research
-
Specialist Training — EndocrinologySpecialist Training
Academic and Clinical Areas of Focus
Dr. Skov’s doctoral and clinical work sits at the intersection of GLP-1 pharmacology and renal physiology — an area of growing relevance as GLP-1 receptor agonists are increasingly prescribed across obesity, type 2 diabetes, and cardiovascular risk management. His research foundation covers the endocrine mechanisms involved in weight regulation, the cardiometabolic effects of incretin-based treatment, and the kidney-function considerations that inform dosing and monitoring decisions for patients with concurrent metabolic and renal conditions.
-
GLP-1 Receptor Agonists — Pharmacology and Metabolic OutcomesResearch Area
-
Kidney Function and Incretin-Based TherapyResearch Area
-
Obesity, Type 2 Diabetes, and Metabolic ComorbidityClinical Focus
How Dr. Skov Reviews Weight-Management Content
Articles submitted for endocrinology review are checked against three reference layers in sequence: (1) the current FDA-approved Prescribing Information for the medication in question — including indications, contraindications, and renal-dosing considerations; (2) the most recent clinical guideline statements from relevant authorities, including the American Diabetes Association Standards of Care, the Endocrine Society Clinical Practice Guidelines on obesity pharmacotherapy, and the American Association of Clinical Endocrinology Comprehensive Diabetes Management Algorithm; and (3) recent peer-reviewed literature on clinical outcomes, particularly in populations with metabolic comorbidities or renal impairment.
Conflict of interest disclosure. Dr. Skov has no financial relationships with any weight-management, GLP-1, or diabetes pharmaceutical manufacturer. He receives a fixed per-article review fee, paid regardless of the article’s conclusions or commercial outcomes. He is not compensated for referrals, traffic, or any user action taken on the platform.
Independence boundary. This is a health education platform. Dr. Skov’s clinical practice is entirely separate from his reviewer role here. No content reviewed under this arrangement is directed to patients under his direct clinical care.